Given that IFIT2/3/5 expression are potential prognosis predictors, we constructed a nomogram integrating patients’ age, cytogenetic risk and the mRNA expression of IFIT2/3/5 to predict the 1-year, 3-year and 5-year survival probability for AML patients (Fig. 3C). Here, IFIT2 is linked to acute myeloid leukemia.